|
|
||||||||



,¶
* Department of Biochemistry, University of Lausanne, Epalinges, Switzerland;
Centre dImmunologie de Marseille-Luminy, Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de la Méditérranée, Marseille, France;
Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland;
INSERM Unité 563, Centre de Physiopathologie de Toulouse-Purpa, Toulouse, F-31300 France;
¶ Département Oncogénèse et Signalisation dans les Cellules Hématopoiétiques, Institut Fédératif de Recherche 30 and Laboratoire dAnatomie Pathologique, Purpans Hospital, Toulouse F-31300, France;
|| INSERM Unité 563, Centre de Physiopathologie de Toulouse-Purpan, Toulouse, F-31300 France; and
# Département de Génétique Fonctionnelle des Maladies des Épithéliums, Institut Fédératif de Recherche 30, Purpans Hospital, Toulouse F-31300, France
LatY136F knock-in mice harbor a point mutation in Tyr136 of the linker for activation of T cells and show accumulation of Th2 effector cells and IgG1 and IgE hypergammaglobulinemia. B cell activation is not a direct effect of the mutation on B cells since in the absence of T cells, mutant B cells do not show an activated phenotype. After adoptive transfer of linker for activation of T cell mutant T cells into wild-type, T cell-deficient recipients, recipient B cells become activated. We show in vivo and in vitro that the LatY136F mutation promotes T cell-dependent B cell activation leading to germinal center, memory, and plasma cell formation even in an MHC class II-independent manner. All the plasma and memory B cell populations found in physiological T cell-dependent B cell responses are found. Characterization of the abundant plasmablasts found in secondary lymphoid organs of LatY136F mice revealed the presence of a previously uncharacterized CD93-expressing subpopulation, whose presence was confirmed in wild-type mice after immunization. In LatY136F mice, B cell activation was polyclonal and not Ag-driven because the increase in serum IgG1 and IgE concentrations involved Abs and autoantibodies with different specificities equally. Although the noncomplement-fixing IgG1 and IgE are the only isotypes significantly increased in LatY136F serum, we observed early-onset systemic autoimmunity with nephritis showing IgE autoantibody deposits and severe proteinuria. These results show that Th2 cells developing in LatY136F mice can trigger polyclonal B cell activation and thereby lead to systemic autoimmune disease.
This article has been cited by other articles:
![]() |
M. Miyaji, R. L. Kortum, R. Surana, W. Li, K. D. Woolard, R. M. Simpson, L. E. Samelson, and C. L. Sommers Genetic evidence for the role of Erk activation in a lymphoproliferative disease of mice PNAS, August 25, 2009; 106(34): 14502 - 14507. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chevrier, C. Genton, A. Kallies, A. Karnowski, L. A. Otten, B. Malissen, M. Malissen, M. Botto, L. M. Corcoran, S. L. Nutt, et al. CD93 is required for maintenance of antibody secretion and persistence of plasma cells in the bone marrow niche PNAS, March 10, 2009; 106(10): 3895 - 3900. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Archambaud, A. Sansoni, M. Mingueneau, E. Devilard, G. Delsol, B. Malissen, and M. Malissen STAT6 Deletion Converts the Th2 Inflammatory Pathology Afflicting LatY136F Mice into a Lymphoproliferative Disorder Involving Th1 and CD8 Effector T Cells J. Immunol., March 1, 2009; 182(5): 2680 - 2689. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang, A. Kissenpfennig, M. Mingueneau, S. Richelme, P. Perrin, S. Chevrier, C. Genton, B. Lucas, J. P. DiSanto, H. Acha-Orbea, et al. Th2 Lymphoproliferative Disorder of LatY136F Mutant Mice Unfolds Independently of TCR-MHC Engagement and Is Insensitive to the Action of Foxp3+ Regulatory T Cells J. Immunol., February 1, 2008; 180(3): 1565 - 1575. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Gorman, A. I. Russell, Z. Zhang, D. Cunninghame Graham, A. P. Cope, and T. J. Vyse Polymorphisms in the CD3Z Gene Influence TCR{zeta} Expression in Systemic Lupus Erythematosus Patients and Healthy Controls J. Immunol., January 15, 2008; 180(2): 1060 - 1070. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |